Biocon Limited has informed the Exchange regarding a press release dated October 23, 2025, titled "Biocon Biologics Receives Health Canada Approval for Yesintek and Yesintek I.V. (ustekinumab), a Biosimilar to Stelara®".
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon's subsidiary, Biocon Biologics, has received approval from Health Canada for Yesintek and Yesintek I.V., a biosimilar version of Stelara (ustekinumab). Stelara is a widely used biologic for autoimmune conditions like psoriasis, Crohn's disease, and ulcerative colitis. This marks entry into the Canadian market for this product. The approval enables Biocon Biologics to commercialize the biosimilar in Canada, expanding its global footprint beyond existing markets.
This is a positive development for Biocon as it opens a new revenue stream in the Canadian market and strengthens the biosimilars portfolio of Biocon Biologics. Shareholders can expect gradual contribution to revenue, though commercial uptake will take time.